BioWorld

June 28, 2006

View Archived Issues

Takeda Takes Global Hematide Rights In $535M Affymax Deal

Entering its first major global partnership, privately held Affymax Inc. turned to its Japanese partner Takeda Pharmaceutical Co. Inc. to grant the rest-of-the-world rights to its anemia drug, Hematide. (BioWorld Today) Read More

Avastin Unsuccessful In Pancreatic Cancer Study

Read More

Tengion Series B Gets $50M For Autologous-Bladder Work

Read More

Cypress, Organon Mull Future Of Mirtazapine Collaboration

Read More

Clinic Roundup

Read More

Other News To Note

Read More